Aytu BioPharma (DB:AY20) - Aandelenkoers, Nieuws & Analyse

AY20 Overzicht aandelen

A pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. Meer informatie

AY20 fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Verhandeld tegen 83.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 67.44% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €8M )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

Aytu BioPharma, Inc. Concurrenten

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Valeo Pharma

DB:VP2

€493.4k

MPH Health Care

DB:93M1

€105.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Aytu BioPharma
Historische aandelenkoersen
Huidige aandelenkoers	US$3.28
52 Week Hoogtepunt	US$20.00
52 Week Laag	US$2.89
Bèta	-0.41
11 maand verandering	0%
3 maanden verandering	1,504.21%
1 Jaar Verandering	-81.83%
33 jaar verandering	-98.71%
5 jaar verandering	n/a
Verandering sinds IPO	-99.80%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	AY20	DE Pharmaceuticals	DE Markt
7D	0%	-1.2%	-0.02%
1Y	-81.8%	-20.1%	8.2%

Rendement versus industrie: AY20 presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -20.1 % opleverde.

Rendement versus markt: AY20 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.2 % opleverde.

Prijsvolatiliteit

Is AY20's price volatile compared to industry and market?
AY20 volatility
AY20 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van AY20 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van AY20 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	164	Josh Disbrow	aytubio.com

Aytu BioPharma, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Aytu BioPharma zich tot de beurswaarde?
AY20 fundamentele statistieken
Marktkapitalisatie	€7.66m
Inkomsten(TTM)	-€71.67m
Inkomsten(TTM)	€96.81m

0.1x

P/S-verhouding

-0.1x

Koers/Winstverhouding

Is AY20 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AY20 resultatenrekening (TTM)
Inkomsten	US$105.58m
Kosten van inkomsten	US$42.73m
Brutowinst	US$62.85m
Overige uitgaven	US$141.02m
Inkomsten	-US$78.17m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-20.69
Brutomarge	59.53%
Nettowinstmarge	-74.04%
Schuld/Eigen Vermogen Verhouding	47.8%

Hoe presteerde AY20 op de lange termijn?

Bekijk historische prestaties en vergelijking

AY20 Overzicht aandelen

Beloningen

Risicoanalyse

Aytu BioPharma, Inc. Concurrenten

XTRA:B8FK

€16.4m

DUSE:SBX

€27.9m

DB:VP2

€493.4k

DB:93M1

€105.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Russ McMahen to Leave as Senior Vice President of Research and Development of Aytu BioPharma, Inc

Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024

An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU).

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024

Recent updates

Russ McMahen to Leave as Senior Vice President of Research and Development of Aytu BioPharma, Inc

Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024

An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU).

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024

Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024

Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. announced delayed annual 10-K filing

Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023

Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Aytu BioPharma, Inc. announced delayed 10-Q filing

Aytu BioPharma, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance

Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma Receives A 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

First quarter 2023 earnings released: US$0.057 loss per share (vs US$1.09 loss in 1Q 2022)

Forecast to breakeven in 2025

Aytu BioPharma, Inc. Announces Management Changes

Aytu BioPharma, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Aytu Biopharma Announces Continuing Availability of Adhd Medication Adzenys Xr-Odt(R) in Response to Reported Generic Adderall(R) Xr Supply Disruptions

Full year 2022 earnings released: US$3.75 loss per share (vs US$3.48 loss in FY 2021)

Aytu BioPharma, Inc. to Report Q4, 2022 Results on Sep 27, 2022

Aytu BioPharma, Inc. Announces Addition of Fourth Patent License for Ar101/Enzastaurin

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu Biopharma, Inc. Appoints Vivian Liu to Its Board of Directors and as Member of the Nominating & Corporate Governance Committee, Effective July 1, 2022

Aytu BioPharma Receives Letter from the Nasdaq

Third quarter 2022 earnings released: US$1.79 loss per share (vs US$1.41 loss in 3Q 2021)

Insufficient new directors

Aytu BioPharma, Inc., Annual General Meeting, May 18, 2022

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021)

Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020)

Forecast to breakeven in 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Independent Director Steven Boyd has left the company

Aytu Biopharma, Inc.(NasdaqCM:AYTU) dropped from Russell 3000E Value Index

Aytu Biopharma, Inc. Plans to Close Grand Prairie, Texas Manufacturing Operations over the Next Eighteen Months

CFO, Secretary & Treasurer has left the company

Independent Director has left the company

Second quarter 2021 earnings released: US$0.72 loss per share (vs US$0.12 loss in 2Q 2020)

Revenue beats expectations

Aytu BioScience, Inc. (NasdaqCM:AYTU) entered into definitive merger agreement to acquire Neos Therapeutics, Inc. (NasdaqGM:NEOS) for $37.8 million.

Aytu BioScience, Inc. to Report Q1, 2021 Results on Nov 12, 2020

Aytu BioScience, Inc. to Report Q4, 2020 Results on Oct 06, 2020

Aytu BioScience, Inc. announced delayed annual 10-K filing

New 90-day low - €0.86

New 90-day low - €1.10

Rendement voor aandeelhouders

Prijsvolatiliteit